Pharmafile Logo
Pharmafocus logo
Advanced Search

migraine

Showing 15 posts of 42 posts found.

Pfizer recall two batches of migraine drug Relpax

August 16, 2019
Medical Communications FDA, Pfizer, Relpax, migraine, pharma, recall

Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination. In a statement on the …

News
lilly_building_with_american_flag_web

Lilly’s Emgality smashes all Phase 3 endpoints in migraine sub-population

August 6, 2019
Manufacturing and Production, Research and Development Eli Lilly, Emgality, migraine, pharma

New Phase 3 data have been revealed on Eli Lilly’s Emgality (galcanezumab-gnlm), detailing its success in meeting all of its …

News
neurons-3743011_960_720

Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial

July 11, 2019
Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma

Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …

News
lilly_entrance_web

Eli Lilly’s Emgality approved in the US for episodic cluster headache

June 5, 2019
Research and Development, Sales and Marketing Eli Lilly, Emgality, episodic cluster headache, migraine, pharma

Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, …

News

FDA approves Theranica’s smartphone-controlled electroceutical device for migraine

May 29, 2019
Research and Development FDA, Nerivio Migra, Theranica, migraine, pharma

Biomedical tech company Theranica has secured FDA approval for Nerivio Migra, its wearable, smartphone-controlled electroceutical device, for the acute treatment …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 10, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, GSK, Innoviva, NHS, Novartis, health, migraine, pharma

This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving …

News
headquarters_3_web

Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine

May 8, 2019
Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …

News
teva_canada_1

Teva’s Ajovy injection secures EU approval for the prevention of migraine

April 2, 2019
Manufacturing and Production, Sales and Marketing EU, Europe, Teva, ajovy, migraine, pharma

Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the European …

News

NICE rejects Novartis’ Aimovig migraine injection for NHS use

January 10, 2019
Sales and Marketing Aimovig, NICE, Novartis, migraine, pharma

It’s disappointing news for Novartis as NICE revealed that it had decided not to recommend Aimovig (erenumab) for routine NHS …

News
lilly_entrance_web

Eli Lilly’s Emgality cleared for treatment of migraine in Europe

November 20, 2018
Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma

Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …

News
sicorbio

FDA greenlights Teva’s migraine drug Ajovy in two dosage options

September 20, 2018
Sales and Marketing FDA, Teva, US, ajovy, migraine, pharma

Israeli drugmaker Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (remanezumab-vfrm) has received FDA approval as a …

News
novartis_outside_1

Novartis migraine prevention drug scores EU approval

July 31, 2018
Manufacturing and Production, Sales and Marketing Aimovig, Europe, Novartis, migraine, pharma

Novartis is celebrating the news that its calcitonin gene-related peptide receptor (CGRP-R) pathway therapy Aimovig (erenumab) has been approved by …

News
allergan

Allergan’s atogepant fulfils primary endpoint in episodic migraine

June 12, 2018
Manufacturing and Production, Research and Development Allergan, atogepant, migraine, pharma

Allergan has made ground in its quest to become “the headache company” with the release of new Phase 2b/3 data …

News
headache

Amgen/Novartis potential blockbuster migraine med gets FDA nod

May 18, 2018
Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical

The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …

News
lilly_entrance_web

Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form

May 16, 2018
Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma

Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026